Vascepa (icosapent ethyl) is approved to reduce cardiovascular risk in adults with elevated triglycerides and other risk factors, often used alongside statins. Common adverse effects include:

- Musculoskeletal pain (up to 5% of patients).
- Peripheral edema (up to 3%).
- Constipation (up to 3%).
- Atrial fibrillation (up to 5%).
- Increased bleeding risk, especially with anticoagulants or antiplatelets.

When combined with statins (a frequent pairing), risks rise for:

- Myopathy or rhabdomyolysis (muscle breakdown), though rare.
- Elevated liver enzymes.
- New-onset diabetes or glycemic control issues in predisposed patients.

Gastrointestinal issues like nausea or diarrhea occur in 3-5% overall. Serious risks include hemorrhagic stroke or hypersensitivity reactions. Monitor for gout flares due to uric acid changes. Full details appear in the prescribing information; consult a healthcare provider for personalized risks.

Sources:
- [1] Vascepa Prescribing Information, Amarin Pharma (https://www.vascepa.com/)
- [2] FDA Label for Vascepa (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202057s019lbl.pdf)